Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole?

İNCEBIYIK, ADNAN; Vural, Mehmet; CAMUZCUOĞLU, HAKAN; TAŞKIN, ABDULLAH; Camuzcuoglu, Aysun; HİLALİ, NEŞE; AKSOY, NURTEN

doi:10.1007/s00508-015-0735-5

Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole?

Atıf İçin Kopyala

İNCEBIYIK A., Vural M., CAMUZCUOĞLU H., TAŞKIN A., Camuzcuoglu A., HİLALİ N. G., ...Daha Fazla

WIENER KLINISCHE WOCHENSCHRIFT, cilt.128, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 128
Basım Tarihi: 2016
Doi Numarası: 10.1007/s00508-015-0735-5
Dergi Adı: WIENER KLINISCHE WOCHENSCHRIFT
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Marmara Üniversitesi Adresli: Evet

Özet

The objective of this study is to evaluate the prognostic value of M30 and M65 levels as markers of apoptotic activity and maternal serum oxidative stress in patients with complete hydatidiform mole (CHM).